Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotechnology company with two novel technology platforms designed to provide relief to those suffering from severe pain while protecting them from abuse and Overdoses, today announced the Company has engaged global investor relations specialists, MZ Group (“MZ”) to lead a comprehensive strategic investor relations and financial communications program in all key markets.

MZ Group will work closely with Ensysce management to develop and implement a comprehensive capital markets strategy designed to increase the company’s visibility within the investment community. The campaign will highlight how Ensysce seeks to improve prescription drug safety by applying its two breakthrough patented technology platforms TAAP™ and MPAR™, designed to prevent opioid abuse and overdose. Ensysce’s lead TAAP opioid, PF614, which was developed to be abuse-resistant and demonstrated in Phase 1 data to be safe without compromising efficacy, is expected to be the company’s first product to market and generate income for ongoing programs. Ensysce has obtained Fast-Track designation from the FDA and uses the 505(b)(2) regulatory pathway, which could significantly reduce trial/regulatory risk and potential time to market and cost.

MZ has developed a distinguished reputation as a premier resource for institutional investors, broker-dealers, analysts and private investors. The company has offices around the world and was recently ranked #7 in the world in corporate communications.

Shannon Devine, Managing Director of MZ North America, will advise Ensysce on all facets of corporate and financial communications, including coordinating roadshows and investment conferences in key cities and brand awareness. with financial and social media.

Ted Haberfield, Chairman and President of MZ Group North America, said, “Ensysce’s breakthrough abuse-resistant opioids are designed to combat prescription drug abuse, an epidemic and one of the drug problems in the world. fastest growing in the United States. The global opioid market is expected to grow to $29.8 billion in 2023, with more than a third of the US population and 20-30% of the global population reporting chronic pain. This is partly due to the aging of the population, as the prevalence of chronic pain increases with a higher incidence of age-related diseases, including cancer, cardiovascular disorders, obesity and diabetes. At the same time, the increasing use of opioids has led to an increase in their abuse linked to the desire to increase the onset of euphoria, its intensity and its duration. Over the past year, more than 200 people have died every day in the United States after an opioid overdose. Ensysce’s new class of pain products creates untapped value that presents an exciting opportunity, and we look forward to sharing this with our network of institutional, family offices and retail investors.

Shannon Devine added, “The TAAP™ and MPAR™ platforms created by Ensysce combine anti-abuse and anti-overdose technology to create new classes of prescription drugs that should be potent and safe for everyone. TAAP™ Opioids are designed with a 2-step verification mechanism that cannot be “cracked” like abuse deterrent formulations, providing a highly effective solution to combat drug abuse. TAAP™ is only activated by trypsin, a digestive enzyme that only exists in the intestine. Therefore, crushing, inhaling, or injecting it will not cause the opioid to be released more rapidly to produce pleasure or euphoria. It also chemically modifies the opioid, eliminating potential abuse by the patient through physical means. MPAR™ is an intelligent anti-overdose platform designed to protect patients from overdose when combined with TAAP™ opioids. MPAR™ inhibits trypsin when too much TAAP™ opioid is swallowed, inhibiting full activation and release of opioids, and therefore preventing overdose-related deaths. MPAR™ is only triggered by an overdose, blocking further doses consumed. Together, these drug platforms help address the unmet need for safer opioid options for people with severe pain.

“Our pipeline of pain, addiction and ADHD candidates developed using TAAP™ and MPAR™ continues to progress,” said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. “More recently, we announced a critical milestone on our journey to FDA approval – the first assay in the bioequivalence (BE) trial of the novel Trypsin Activated Abuse Protected (TAAP) opioid, PF614. Additionally, in the fourth quarter of 2021, we successfully closed a $15 million financing that provided us with the proceeds needed to continue advancing our major clinical trial programs. We continue to develop the next generation of innovative solutions to combat the potential for opioid abuse and look forward to working with Shannon and the entire MZ Group team to communicate the value of our technology to create value at long term for our shareholders. concluded Kirkpatrick.

For more information about Ensysce, please visit the company’s website at www.ensysce.com. To schedule a conference call with management, please email your request to ENSC@mzgroup.us or call Shannon Devine at 203-741-8811.

About MZ Group

MZ North America is the US division of MZ Group, a global leader in investor relations and corporate communications. MZ provides innovative and personalized services to national and multinational private and public companies in all sectors through a unique and fully integrated “one-stop-shop” approach. By providing a full range of products and services through a single point of contact, MZ offers services to all relevant markets aimed at helping our customers build a lasting public brand. MZ North America has a global presence with offices located in New York, Chicago, San Diego, Aliso Viejo, Austin, Minneapolis, Taipei and São Paulo. For more information, please visit www.mzgroup.us.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, California, is a clinical-stage biotechnology company that uses its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the company is developing a new class of potent, tamper-proof opioids that both prevent abuse drugs and overdoses. Ensysce’s products are expected to provide safer options to treat severe pain and help prevent deaths from opioid abuse, thereby reducing human and economic cost. The platforms are covered by an extensive global intellectual property portfolio for a wide range of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-looking statements

Statements in this press release that are not purely historical may be considered forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may”, “intends”, “may”, “could”, “shall”, “expect”, “plan” and other similar expressions are intended to identify statements. The product candidates discussed are in the clinic and unapproved and there can be no assurance that the clinical programs will succeed in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that a product candidate to receive regulatory approval or be successfully marketed. All forward-looking statements are based on estimates and assumptions made by Ensysce’s management which, although Ensysce believes them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including, among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations regarding regulatory submissions and approvals; potential safety issues relating to or the effectiveness of Ensysce’s product candidates; the availability or commercial potential of product candidates; Ensysce’s ability to fund its ongoing operations, including its planned clinical trials; the dilutive effect of equity issues from our fundraising; and the ability of Ensysce and its partners to operate within their license, collaboration and manufacturing agreements. These statements are also subject to a number of important risks and uncertainties which are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available free of charge at the website of the SEC at www. .sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Ensysce Biosciences company contact:
Lynn Kirkpatrick, Ph.D.
Chief executive officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811

Source: Ensysce Biosciences Inc.

Comments are closed.